Press releases

24 November 2017

Horama raises €19 million in a Series B financing round

Horama raises 19 million euros from new investors (Kurma Partners, Fund+, Pontifax and Idinvest) and existing investors (Omnes Capital, GO Capital and Sham Innovation Santé/Turenne) to […]
11 October 2017

Horama Granted Authorization to Conduct Phase I/II Clinical Study for HORA-PDE6B, in Retinitis Pigmentosa (RP)

Paris , October 11, 2017 – Horama, a French biotech co mpany based in Paris and Nantes, which specialises in gene therapy for the treatment of […]
10 July 2017

Horama Granted Orphan Drug Designation (ODD) In U.S. For Drug Candidate HORA-RLBP1

Paris, France, July 10, 2017 – Horama (, a French biotech company based in Paris and specialized in gene therapy for the treatment of rare inherited […]
29 June 2017

Horama welcomes three new experts to bolster its team

• Jean – Yves Deslandes – Chief Medical Officer • Nicolas Delaunay – Head of CMC Regulatory Affairs • Jérôme Vailland – Chief Financial Officer   […]
11 July 2016

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital

Proceeds from this fundraising will be used to: Bring HORA-PDE6B into the clinic, Accelerate HORA-RLPB1 development, Reinforce Horama’s team. Paris, France, July 8, 2016 – Horama, one […]
11 July 2016
Christine Placet

Horama appoints Christine Placet as Managing Director

Paris, France, July 6, 2016 – Horama, one of the leaders in ophthalmic diseases gene therapy, announces the appointment of Christine Placet as Managing Director, reinforcing […]
3 March 2015
logo BPIFrance

HORAMA gets €450,000 from BPIfrance to fight against blindness

The young company aims at becoming a European leader in gene therapy for the treatment of rare genetic diseases in ophthalmology for which no treatment exists […]